A study to see if a drug called gemtuzumab ozogamicin is a useful treatment for patients with immune disorders called haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS), or for patients with cancer

ISRCTN ISRCTN89158144
DOI https://doi.org/10.1186/ISRCTN89158144
EudraCT/CTIS number 2020-002428-36
IRAS number 285470
Secondary identifying numbers CPMS 47063, Grant Code CCLGA 2019 30, IRAS 285470
Submission date
03/12/2020
Registration date
15/12/2020
Last edited
05/04/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Immune system disorders cause abnormally low activity or over activity of the immune system. We want to improve the treatment of patients with immune disorders called haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) which has come back (relapsed) or has not responded to previous treatment (refractory). We also want to improve treatment for those with cancers that have relapsed or are refractory to treatment.
Specifically, we are studying:
• Whether a drug called gemtuzumab ozogamicin elicits a biological response.
• Whether gemtuzumab ozogamicin works against HLH/MAS and cancer and is safe.

Who can participate?
Patients who have been diagnosed with primary or secondary HLH/MAS that is relapsing/refractory to treatment at time of enrolment or have a solid cancer which is refractory to treatment or they have relapsed.

What does the study involve?
Gemtuzumab ozogamicin will be given every 3 weeks for a total of 3 doses via an infusion into the vein (a needle in the arm or via a central line). Each infusion will be given in this hospital and take two hours. During each treatment the patient will have their blood pressure, heart rate and
temperature measured whilst gemtuzumab ozogamicin is being administered. On weeks 2 and week 3 and for two weeks following the third dose, gemtuzumab ozogamicin will not be given but participants will still have a physical examination, blood tests, and an assessment of disease
will in previous weeks.
In addition, the following extra research samples will be taken from the patients:
Blood will be collected for research. This sample will be used in laboratory studies to understand if gemtuzumab ozogamicin treatment has reduced the number of CD33 immune cells and for additional research studies.

What are the possible benefits and risks of participating?
We hope that patients treated with gemtuzumab ozogamicin will have a reduction in CD33 immune cells, and this may improve their current symptoms and disease.
However, we cannot promise that the patients will benefit from participating in this trial as this is the first time gemtuzumab ozogamicin has been tested in people with these conditions.
All the information that we get from this trial will be used to help improve the future treatment of people with HLH/MAS and/or refractory or relapsed solid cancers.
Although gemtuzumab ozogamicin has not been given to people with HLH/MAS or solid cancer before, it has been used to treat people with other conditions. Therefore we know what most of the side effects of treatment are.

Where is the study run from?
Cancer Research UK Clinical Trials Unit at the University of Birmingham (UK)

When is the study starting and how long is it expected to run for?
February 2020 to March 2025

Who is funding the study?
Little Princess Trust via the Children's Cancer and Leukaemia Group (UK) and Eveson Charitable Trust (UK)

Who is the main contact?
The main contact is the trial coordinator at the Cancer Research UK Clinical Trials Unit at gotham@trials.bham.ac.uk. They will be able to put you in touch with the chief investigator of the trial if this is required.

Contact information

Prof Gary Middleton
Principal Investigator

School of Cancer Sciences
University of Birmingham
Edgbaston

Birmingham
B15 2TT
United Kingdom

ORCiD logoORCID ID 0000-0001-5695-3474
Phone +44 (0)121 371 2000
Email G.Middleton@bham.ac.uk

Study information

Study designInterventional non-randomized study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet.
Scientific titleA phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours (GOTHAM)
Study acronymGOTHAM
Study hypothesisCurrent study hypothesis as of 16/03/2023:
Gemtuzumab ozogamicin 3 mg/m2/dose given on Days 1, 22, and 43 has an effect on the levels of CD33+ myeloid cells in the blood in two parallel groups: patients with primary or secondary HLH or MAS disease that is relapsing/refractory to treatment at the time of enrolment and patients with relapsed/refractory solid tumours)

Previous study hypothesis:
Gemtuzumab ozogamicin 3 mg/m2/dose given on Days 1, 8, and 15 has an effect on the levels of CD33+ myeloid cells in the blood in two parallel groups: patients with primary or secondary HLH or MAS disease that is relapsing/refractory to treatment at the time of enrolment and patients with relapsed/refractory solid tumours)
Ethics approval(s)Approved 02/12/2020, South Central - Hampshire A Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 1048033; hampshirea.rec@hra.nhs.uk), ref: 20/SC/0362
ConditionHaemophagocytic lymphohistiocytosis, macrophage activation syndrome, relapsed/refractory solid tumours
InterventionCurrent interventions as of 16/03/2023:
GOTHAM is a Phase II multicentre clinical trial of gemtuzumab ozogamicin. The trial aims to determine whether gemtuzumab ozogamicin elicits a biological response (a change in the number of CD33-positive cells) and whether it works against HLH/MAS and cancer and is safe. There are also other exploratory biological endpoints.
Potential patients and their parents/guardian/legal representative (if applicable) will be approached by a Consultant or delegate working on this study. If the patient and their parent/guardian/legal representative are satisfied with the age-appropriate information given and have had the chance to discuss the study with both the research team and their family and friends, they will be asked to sign a consent form if they wish to participate.

Before treatment starts:
The patient will undergo the following tests which would typically be part of the patient's standard of care if receiving treatment for their disease:
•Physical examination (including weight)
•Measurement of blood pressure, heart rate, and temperature
•Blood tests
•Pregnancy test (for female patients of child-bearing potential only)
•Assessment of their disease. How this is done is dependent on the type of disease. This may involve Blood tests (if the patient has HLH/MAS) or scans (if the patient has cancer- routine care for these patients).

During treatment:
Gemtuzumab ozogamicin will be given once every 3 weeks for 3 doses via an infusion into their vein (a needle in the arm or via a central line). Each infusion will be given in this hospital and take two hours. Around 1 hour before treatment with gemtuzumab ozogamicin, pre-medication
drugs will be given in order to reduce the chance of having a reaction. These drugs will include a steroid, an antihistamine and paracetamol.
During each treatment the participant will have their blood pressure, heart rate and temperature measured whilst gemtuzumab ozogamicin is being administered.

Before each treatment (i.e. once a week) the patient will be assessed by the doctor or nurse to see how they have been. They will be physically examined including measuring weight (and height at the first visit). Blood tests performed to ensure it is safe to deliver the treatment and to monitor disease.

An assessment of disease will be performed during treatment: blood tests for HLH/MAS patients will be performed weekly. Scans will only be performed in cancer patients if part of routine care.

In addition, we would like to take extra blood samples. This involves providing between 3 - 7 teaspoons of blood (depending on if a child or an adult) before treatment. These samples will be used in laboratory studies to understand if gemtuzumab ozogamicin treatment has reduced the number of CD33 immune cells (primary endpoint) and for exploratory endpoint analysis:
• To assess the change in IL-1/IL-6/TNF-α in the plasma
• To assess the change of CD33+ cells in the bone marrow/ tumour tissue (as available)

On weeks 2 and week 3, gemtuzumab ozogamicin will not be given but there will still be a physical examination, blood tests, and an assessment of disease like in previous weeks. In addition, we would again like to take the 3 - 7 teaspoons extra blood for the primary endpoint analysis and exploratory research. These same assessments will also be done in the 2 weeks after the last dose of gemtuzumab ozogamicin.

If the patient has solid cancer, scans may be performed to monitor the disease. These scans will only be performed if requested as part of standard treatment.

After treatment has completed, assessments will be performed according to the hospital’s usual routine practice and no extra samples are required for the trial unless the participant progresses or relapses.

All patients will be followed-up for a minimum of one year after the end of treatment.

Further samples for research: Patients will be asked if they wish to consent to donate excess bone marrow and tumour tissue samples available from procedures done as routine practice either before or during the trial for research purposes. No additional interventions are required.

Previous interventions:
GOTHAM is a Phase II multicentre clinical trial of gemtuzumab ozogamicin. The trial aims to determine whether gemtuzumab ozogamicin elicits a biological response (a change in the number of CD33-positive cells) and whether it works against HLH/MAS and cancer and is safe. There are also other exploratory biological endpoints.
Potential patients and their parents/guardian/legal representative (if applicable) will be approached by a Consultant or delegate working on this study. If the patient and their parent/guardian/legal representative are satisfied with the age-appropriate information given and have had the chance to discuss the study with both the research team and their family and friends, they will be asked to sign a consent form if they wish to participate.

Before treatment starts:
The patient will undergo the following tests which would typically be part of the patient's standard of care if receiving treatment for their disease:
•Physical examination (including weight)
•Measurement of blood pressure, heart rate, and temperature
•Blood tests
•Pregnancy test (for female patients of child-bearing potential only)
•Assessment of their disease. How this is done is dependent on the type of disease. This may involve Blood tests (if the patient has HLH/MAS) or scans (if the patient has cancer- routine care for these patients).

During treatment:
Gemtuzumab ozogamicin will be given once a week for 3 weeks via an infusion into their vein (a needle in the arm or via a central line). Each infusion will be given in this hospital and take two hours. Around 1 hour before treatment with gemtuzumab ozogamicin, pre-medication drugs will be given in order to reduce the chance of having a reaction. These drugs will include a steroid, an antihistamine and paracetamol.
During each treatment the participant will have their blood pressure, heart rate and temperature measured whilst gemtuzumab ozogamicin is being administered.

Before each treatment (i.e. once a week) the patient will be assessed by the doctor or nurse to see how they have been. They will be physically examined including measuring weight (and height at the first visit). Blood tests performed to ensure it is safe to deliver the treatment and to monitor disease.

An assessment of disease will be performed during treatment: blood tests for HLH/MAS patients will be performed weekly. Scans will only be performed in cancer patients if part of routine care.

In addition, we would like to take extra blood samples. This involves providing between 3 - 7 teaspoons of blood (depending on if a child or an adult) before treatment. These samples will be used in laboratory studies to understand if gemtuzumab ozogamicin treatment has reduced the number of CD33 immune cells (primary endpoint) and for exploratory endpoint analysis:
• To assess the change in IL-1/IL-6/ TNF-α in the plasma
• To assess the change of CD33+ cells in the bone marrow/ tumour tissue (as available)

On weeks 4 and week 5, gemtuzumab ozogamicin will not be given but there will still be a physical examination, blood tests, and an assessment of disease like in previous weeks. In addition, we would again like to take the 3 - 7 teaspoons extra blood for the primary endpoint analysis and exploratory research.

If the patient has solid cancer, scans may be performed to monitor the disease. These scans will only be performed if requested as part of standard treatment.

After 5 weeks assessments will be performed according to the hospital’s usual routine practice and no extra samples are required for the trial unless the participant progresses or relapses.

All patients will be followed-up for a minimum of one year after the end of treatment.

Further samples for research: Patients will be asked if they wish to consent to donate excess bone marrow and tumour tissue samples available from procedures done as routine practice either before or during the trial for research purposes. No additional interventions are required.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Gemtuzumab ozogamicin
Primary outcome measureCurrent primary outcome measure as of 16/03/2023:
CD33+ cell count in the blood samples of patients collected on day 1, day 8, day 15, day 22, 43, 50 and 57

Previous primary outcome measure:
CD33+ cell count in the blood samples of patients collected on day 1, day 8, day 15, day 22 and day 29
Secondary outcome measuresMeasured using patient records up to 1 year after the end of treatment:
1. Overall Survival time - defined as the time from the date of entry into the trial to the date of death
2. Progression-free survival (PFS) time (Group 2 only) - defined as the time from the date of entry into the trial to the date of disease progression
3. Grade 3 and 4 adverse events
Overall study start date01/02/2020
Overall study end date01/03/2025

Eligibility

Participant type(s)Patient
Age groupMixed
Lower age limit1 Year
SexBoth
Target number of participantsPlanned Sample Size: 20; UK Sample Size: 20
Participant inclusion criteria1. Aged >1 year old at the time of trial entry
2. Diagnosis of primary or secondary HLH or MAS disease that is relapsing/refractory to treatment at time of enrolment (Group 1)
OR
3. Histologically confirmed diagnosis of solid cancer with radiological or clinical evidence of disease progression (during or after completion of at least one previous treatment) or any subsequent recurrence (biopsy at relapse is not mandated) (Group 2)
Note: patients who meet the inclusion criteria for both groups 1 and 2 should be entered into group 1
3.1.Group 2 only – must have adequate liver function:
3.1.1. Total bilirubin ≤x2 upper limit of normal (ULN)
3.1.2. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤2.5 x ULN
4. Documented negative pregnancy test for female patients of childbearing potential within 7 days prior to trial entry
5. Sexually active patients must agree to use 2 methods of adequate and appropriate contraception while on trial drug and for 4 months (male) and 7 months (female) following treatment discontinuation
6. Written informed consent given by patient and/or parents/legal guardian
Participant exclusion criteria1. Evidence of sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD)
2. Previous treatment with another CD33 targeting antibody or immunotoxin
3. Hypersensitivity to gemtuzumab ozogamicin or to any of the excipients
4. Pregnant or lactating female
Recruitment start date30/06/2021
Recruitment end date31/12/2023

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

Birmingham Women's and Children's NHS Foundation Trust
Steelhouse Lane
Birmingham
B4 6NH
United Kingdom
Queen Elizabeth Hospital
University Hospitals Birmingham NHS Foundation Trust
Mindelsohn Way
Edgbaston
Birmingham
B15 2GW
United Kingdom

Sponsor information

University of Birmingham
University/education

Room 117
Aston Webb Building
Edgbaston
Birmingham
B15 2TT
England
United Kingdom

Phone +44 (0)121 415 8011
Email researchgovernance@contacts.bham.ac.uk
Website http://www.birmingham.ac.uk/index.aspx
ROR logo "ROR" https://ror.org/03angcq70

Funders

Funder type

Charity

Children's Cancer and Leukaemia Group
Government organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Children's Cancer & Leukaemia Group, UK Children's Cancer and Leukaemia Group, THE CHILDREN'S CANCER AND LEUKAEMIA GROUP, CCLG
Location
United Kingdom
Eveson Charitable Trust

No information available

Results and Publications

Intention to publish date01/03/2026
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.
IPD sharing planThe current data sharing plans for this study are unknown and will be available at a later date

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No

Editorial Notes

05/04/2023: Contact details updated.
16/03/2023: The following changes were made to the trial record:
1. The study hypothesis, interventions and primary outcome measures were updated.
2. The recruitment end date was changed from 01/02/2023 to 31/12/2023.
3. Great Ormond Street Hospital was removed as a trial participating centre.
30/06/2021: The recruitment start date has been changed from 01/06/2021 to 30/06/2021.
19/04/2021: The recruitment start date was changed from 01/04/2021 to 01/06/2021.
16/02/2021: The recruitment start date has been changed from 01/02/2021 to 01/04/2021.
03/12/2020: Trial’s existence confirmed by National Institute for Health Research (NIHR).